Every Form 4 that Intellia Therapeutics, Inc (NTLA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NTLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTLA filings page.
Intellia Therapeutics, Inc. (NTLA) reported that President and CEO John M. Leonard sold shares of Common Stock in two open-market transactions under a pre-arranged Rule 10b5-1 trading plan. On August 20, 2026, he sold 19,890 shares at a weighted average price of $12.60 per share, in multiple trades between $12.32 and $13.00. On August 21, 2026, he sold an additional 2,785 shares at $13.00 per share. The filing also notes 58,415 shares of common stock held indirectly by the John M. Leonard 2015 Irrevocable Trust.
Intellia Therapeutics EVP and CFO Edward J. Dulac III reported a mandatory sell-to-cover sale of 8,111 shares of common stock on July 22, 2026 to satisfy tax withholding from RSU vesting. The shares were sold at a weighted average price of $11.25, within a range from $11.25 to $11.28, leaving 148,175 shares directly owned.
Intellia Therapeutics, Inc. executive Michael P. Dube, VP and Chief Accounting Officer, reported a sale of 2,641 shares of common stock on July 1, 2026 at a weighted average price of $16.78 per share.
According to the disclosure, this was a mandatory “sell-to-cover” transaction to satisfy tax withholding obligations triggered by the vesting of restricted stock units (RSUs) on the same date, and is explicitly described as not a voluntary trade. After this tax-related sale, Dube held 66,886 shares of Intellia common stock directly.
Intellia Therapeutics EVP and CFO Edward J. Dulac III sold 4,677 shares of Common Stock in an open-market transaction. The sale took place on July 2, 2026 at a price of $18.00 per share and was executed under a pre-established Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, Dulac directly holds 156,286 shares of Intellia Therapeutics common stock, indicating he retains a substantial equity stake despite this planned sale.
Intellia Therapeutics director Frank Verwiel received new equity awards. He was granted 9,200 restricted stock units, each representing a contingent right to receive one share of Intellia common stock. Following this grant, he holds 35,148 common shares directly.
He was also awarded a stock option for 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders, and expires on June 8, 2036.
Intellia Therapeutics director Georgia Keresty received equity compensation in the form of restricted stock units and stock options. She acquired 9,200 shares of common stock at no cost through a grant of restricted stock units, bringing her direct holdings to 41,083 shares.
Keresty was also granted stock options covering 13,300 shares of common stock at an exercise price of $12.89 per share. According to the terms, this option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following the grant date.
Intellia Therapeutics, Inc. director Jesse Goodman reported equity awards consisting of common stock and stock options as part of compensation. He received 9,200 shares of Common Stock$0.00 per share33,559 shares
Goodman also received a stock option for 13,300 shares of Common Stock$12.89 per share13,300 shares
Intellia Therapeutics director Brian Goff received new equity compensation awards. He was granted 9,200 restricted stock units, each representing one share of common stock, and stock options covering 13,300 shares at an exercise price of $12.89. Following the grant, he directly holds 32,609 common shares, and the options vest in full on the earlier of one year from grant or the next annual stockholder meeting.
Intellia Therapeutics, Inc. director Fred E. Cohen received new equity-based compensation. He was granted 9,200 restricted stock units, each representing a contingent right to one share of Intellia common stock, increasing his direct common stock holdings to 216,653 shares.
He was also granted a stock option covering 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders, and expires on June 8, 2036.
Intellia Therapeutics director William J. Chase received new equity awards. On June 9, he was granted 9,200 restricted stock units, each representing the right to receive one share of Intellia common stock upon vesting.
He also received a stock option covering 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the grant date or the next annual stockholders’ meeting. After the RSU grant, Chase directly holds 143,893 common shares.
Intellia Therapeutics director Muna Bhanji received new equity awards. She was granted 9,200 shares of common stock based on restricted stock units, bringing her direct common stock holdings to 36,403 shares.
She was also granted stock options for 13,300 shares at an exercise price of $12.89 per share. These options vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders, and expire on June 8, 2036.
LEONARD JOHN M reported acquisition or exercise transactions in this Form 4 filing.
Intellia Therapeutics, Inc. President and CEO John M. Leonard reported equity awards and updated his holdings. He received a stock option for 225,400 shares of common stock, granted at a price of $0.00 per share. He was also granted 156,400 shares of common stock in the form of restricted stock units, each representing a contingent right to receive one share of Intellia common stock. The option was granted on March 1, 2026, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. After these awards, he directly owned 1,169,739 shares of common stock and indirectly held 58,415 shares through the John M. Leonard 2015 Irrevocable Trust.
Intellia Therapeutics EVP and General Counsel James Basta reported routine equity compensation changes and a small tax-related share sale. On March 1, 2026, he received a grant of 65,829 stock options and 46,080 shares of common stock as equity awards. The option grant vests 33% on January 1, 2027, with the remaining 67% vesting in 24 equal monthly installments after that date. On March 2, 2026, 1,211 shares of common stock were sold at $13.78 per share in a mandatory sell-to-cover transaction to satisfy tax withholding on vested restricted stock units, described as not a voluntary trade by the reporting person.
Intellia Therapeutics executive vice president and chief medical officer David Lebwohl reported equity awards on Common Stock and stock options. On March 1, 2026, he acquired stock options for 14,204 shares at an exercise price of $0.00 per share under a grant, award, or other acquisition.
He also acquired 9,943 shares of Common Stock at $0.00 per share through a grant of restricted stock units, each representing a contingent right to receive one share of Intellia common stock. Following these grants, his directly owned Common Stock position is 131,192 shares.
Dulac Edward J III reported acquisition or exercise transactions in this Form 4 filing.
Intellia Therapeutics EVP and CFO Edward J. Dulac III reported new equity awards. On March 1, 2026, he received a stock option for 87,543 shares of common stock and a grant of 61,280 shares of common stock in the form of restricted stock units.
The option was granted with 33% vesting on January 1, 2027, and the remaining 67% vesting in 24 substantially equal monthly installments after that date. Following the common stock award, his directly held common stock position increased to 160,963 shares.
Intellia Therapeutics EVP and Chief Scientific Officer Birgit C. Schultes received new equity awards. On March 1, 2026, she was granted stock options for 56,000 shares of Intellia common stock at an exercise price of $0.00 per share and 39,200 shares of common stock as a grant.
The common stock grant is based on restricted stock units, each representing a contingent right to receive one share of Intellia common stock. The option grant vests with 33% on January 1, 2027, and the remaining 67% in 24 substantially equal monthly installments after that date.
Intellia Therapeutics EVP and Chief Technical Officer Eliana Clark reported a mix of equity awards and a small tax-related sale. Clark received 7,353 shares of common stock from a grant of restricted stock units and a stock option for 10,505 shares. On a separate date, 607 shares were automatically sold at $13.78 per share to cover tax withholding obligations, leaving 93,864 common shares held directly afterward.
Intellia Therapeutics VP and Chief Accounting Officer Michael P. Dube received an equity award in the form of restricted stock units. On the reported date, he acquired 17,250 shares of Intellia common stock through a grant, at a stated price of $0.00 per share.
The award is structured as restricted stock units, each representing a contingent right to receive one share of Intellia common stock. Following this grant, Dube’s directly held common stock position reported in this filing increased to 69,527 shares.
Intellia Therapeutics, Inc. President and CEO John M. Leonard, who is also a director, reported a mandatory sell-to-cover stock transaction. On January 5, 2026, he sold 34,146 shares of common stock at $9.21 per share to cover tax withholding obligations arising from the vesting of restricted stock units on January 1, 2026. The filing states this was not a voluntary trade. After this transaction, Leonard beneficially owned 1,013,339 common shares directly and an additional 58,415 common shares indirectly held by the John M. Leonard 2015 Irrevocable Trust.
Intellia Therapeutics EVP and Chief Scientific Officer Birgit C. Schultes reported a mandatory tax-related stock sale. On January 5, 2026, she sold 8,508 shares of Intellia Therapeutics common stock at a price of $9.21 per share. A footnote explains this was a required “sell-to-cover” transaction to satisfy tax withholding obligations upon the vesting of restricted stock units on January 1, 2026, and not a voluntary trade. Following this transaction, she beneficially owned 98,533 shares of Intellia common stock, which include 925 and 932 shares acquired under the company’s 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.
Intellia Therapeutics executive James Basta reported a tax-related stock sale. On January 5, 2026, he sold 10,397 shares of Intellia Therapeutics common stock at a price of $9.21 per share. According to the filing, this was a mandatory “sell-to-cover” transaction to satisfy his tax withholding obligation from restricted stock units that vested on January 1, 2026, and it is explicitly described as not a voluntary trade. After this transaction, he beneficially owned 101,528 shares of Intellia common stock directly.
Intellia Therapeutics, Inc. director Fred E. Cohen reported an open market purchase of the company’s common stock. On January 5, 2026, he bought 150,000 shares of common stock at a weighted average price of $9.35 per share, coded as a purchase transaction.
According to the filing, these shares were acquired in multiple trades at prices ranging from $9.13 to $9.68. Following this transaction, Cohen beneficially owns 207,453 shares of Intellia Therapeutics common stock held directly.
Intellia Therapeutics EVP and Chief Medical Officer David Lebwohl reported a sale of common stock that was carried out solely to cover taxes on recently vested restricted stock units. On January 5, 2026, he sold 11,903 shares of Intellia Therapeutics common stock at $9.21 per share in a mandatory "sell-to-cover" transaction tied to RSUs that vested on January 1, 2026. After this transaction, Lebwohl beneficially owned 121,249 shares of Intellia common stock. This total includes 1,022 shares and 1,264 shares that were previously acquired through the company’s 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.
Intellia Therapeutics executive Eliana Clark reported an automatic share sale related to taxes. A Form 4 shows that on January 5, 2026, the EVP and Chief Technical Officer sold 9,515 shares of Intellia Therapeutics common stock at $9.21 per share. The filing explains this was a mandatory “sell-to-cover” transaction to satisfy her tax withholding obligation upon the vesting of restricted stock units on January 1, 2026, and does not represent a volitional trade by the reporting person.
After this transaction, she beneficially owns 87,118 shares of Intellia common stock, including 1,264 shares acquired under the company’s 2016 Employee Stock Purchase Plan on December 31, 2025.
Intellia Therapeutics EVP and CFO Edward J. Dulac III reported an automatic sale of company stock. On January 5, 2026, he sold 6,379 shares of Intellia Therapeutics common stock at a price of $9.21 per share. According to the disclosure, this was a mandatory “sell-to-cover” transaction to satisfy tax withholding obligations tied to restricted stock units that vested on January 1, 2026, and it is described as not being a voluntary trade by the executive. After this transaction, he beneficially owns 99,683 shares of Intellia Therapeutics common stock directly.
Intellia Therapeutics VP and Chief Accounting Officer Michael P. Dube reported a small insider stock sale linked to tax withholding. On January 5, 2026, he sold 2,989 shares of Intellia common stock at $9.21 per share, leaving him with 52,277 shares held directly after the transaction.
According to the footnote, this was a mandatory “sell-to-cover” transaction carried out to satisfy his tax withholding obligations arising from the vesting of restricted stock units (RSUs) on January 1, 2026. The disclosure states that this sale does not represent a voluntary trading decision by the reporting officer but an automatic sale tied to equity award taxation.
Intellia Therapeutics' President and CEO, who is also a director, reported stock option exercises and related share sales in company stock. On 12/11/2025, the reporting person exercised options to acquire 49,959 shares of common stock at an exercise price of $ 6.83 and sold 49,959, 32,832 and 5,355 shares in separate transactions with weighted average prices of $ 9.49, $ 9.47 and $ 9.59, respectively.
On 12/12/2025, additional options for 8,557 shares were exercised at $ 6.83. These option awards were granted under the company’s 2015 Stock Option and Incentive Plan and had vested in full as of 12/11/2025. The filing notes that the sales occurred automatically under a Rule 10b5‑1 trading plan adopted on 09/11/2025. Following these transactions, the reporting person beneficially owns 1,047,485 shares directly and 58,415 shares indirectly through the John M. Leonard 2015 Irrevocable Trust.
Intellia Therapeutics (NTLA) reported an insider transaction by its EVP and Chief Scientific Officer. On October 1, 2025, the officer executed a mandatory sell-to-cover of 31 shares of common stock at $17.38 to satisfy tax withholding upon RSU vesting, which the filing notes was not a voluntary trade.
Following the transaction, the officer directly beneficially owned 105,184 shares of Intellia common stock.
Michael P. Dube, Vice President and Chief Accounting Officer of Intellia Therapeutics, Inc. (NTLA), reported a Form 4 disclosing a mandatory tax-withholding sale related to RSU vesting. On 10/01/2025 the reporting person had 1,871 shares sold (transaction code S(1)) at $17.38 per share to satisfy tax withholding obligations arising from RSU vesting. After the sale, the reporting person beneficially owned 55,266 shares. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025. The filing describes the sale as non-volitional and linked solely to tax withholding.